juan iovanna | Personalized Medicine | Best Researcher Award

Posted on 21/05/202521/05/2025 by sciencefather

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity

Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Posted on 22/04/202522/04/2025 by sciencefather

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Sebastian Ludwig | Clinical Trials | Best Research Article Award

Posted on 03/04/202503/04/2025 by sciencefather

Sebastian Ludwig | Clinical Trials | Best Research Article Award

Assist. Prof. Dr. Sebastian Ludwig, Universität zu Köln, Germany

Dr. Sebastian Ludwig (b. 1982, Leipzig) is a distinguished gynecologist and urogynecologist, currently serving as Senior Consultant and Head of the Continence and Pelvic Floor Center at the University of Cologne. He earned his medical degree from Ruhr-University Bochum (2009) and completed his habilitation in 2023, focusing on standardization in urogynecological surgery. Dr. Ludwig is a certified clinical trial leader and expert in minimally invasive surgery. Passionate about women’s health, he plays a vital role in medical education. Married with one child, he resides in Cologne.

Publication Profile

Scopus

Education

Assist. Prof. Dr. Sebastian Ludwig 🎓 holds a Doctor of Medicine degree (magna cum laude) and has further distinguished himself by completing his habilitation, earning the venia legendi in Gynecology and Obstetrics. 🏥 His academic journey reflects a deep commitment to medical education, clinical research, and advancing women’s healthcare. With a passion for innovation and evidence-based practice, Dr. Ludwig continues to contribute significantly to his field, shaping the future of gynecological and obstetric medicine. His dedication to both patient care and academic excellence makes him a respected figure in medical education and research. 🔬📚

Experience

Assist. Prof. Dr. Sebastian Ludwig 🏥 has advanced through the medical ranks, starting as an assistant physician and progressing to Oberarzt (senior physician) at the University of Cologne’s Women’s Clinic. His expertise and leadership extend further as the Head of the Continence and Pelvic Floor Center, where he plays a pivotal role in specialized patient care and groundbreaking research. 🔬 His dedication to women’s health, particularly in urogynecology, underscores his commitment to improving treatment outcomes and advancing medical knowledge. Through his clinical and academic contributions, Dr. Ludwig continues to shape the future of gynecological care. 👨‍⚕️📚

Awards

Assist. Prof. Dr. Sebastian Ludwig 🎓 holds multiple prestigious certifications in clinical trials, urogynaecology, gynecological endoscopy, and medical research methodologies. 🏥🔬 These qualifications reflect his dedication to continuous professional development and adherence to the highest standards of research ethics. His expertise in cutting-edge medical techniques ensures optimal patient care and contributes to the advancement of gynecological science. 📚 His commitment to lifelong learning and innovation strengthens his role as a leading specialist in women’s health, making significant contributions to both clinical practice and academic research. 👨‍⚕️💡

Research Focus

Assist. Prof. Dr. Sebastian Ludwig is a dedicated researcher in minimally invasive gynecologic surgery 🏥🔬, with a primary focus on laparoscopic and open abdominal procedures for treating pelvic organ prolapse and related conditions. His work integrates advanced surgical techniques 🏗️, interdisciplinary approaches, and long-term patient outcomes 📊. His studies on uterine ligament replacement and colorectal-gynecological procedures contribute to improving women’s healthcare 👩‍⚕️💙. His research also explores trends in obstetrics 🤰📉, offering insights into evolving birth practices. With publications in top medical journals 📖🏆, Dr. Ludwig plays a crucial role in advancing female pelvic reconstructive surgery 🩺✨.

Publication Top Notes

Comparison of Open Abdominal and Laparoscopic Bilateral Uterosacral Ligament Replacement: A One-Year Follow-Up Study

Early safety and efficiency outcomes of a novel interdisciplinary laparoscopic resection rectopexy combined with sacrocolpopexy for women with obstructive defecation syndrome and pelvic organ prolapse: a single center study

Shifting Trends in Obstetrics: An 18-year Analysis of Low-risk Births at a German University Hospital

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Posted on 03/04/202503/04/2025 by sciencefather

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[¹⁸F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial

2-[¹⁸]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

Yu Liu | Drug Discovery and Development | Best Researcher Award

Posted on 03/04/202503/04/2025 by sciencefather

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry 🧪 at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences 🎓. He was enrolled as a full-time student from September 2008 to July 2011 📅. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree 🎖️. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development 💊. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences 🔬.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director 🏛️ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center 🔬. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research 💊. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry 🧪. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry 🌍.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees 🏛️, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics 📊. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare 💡💰. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements 💊. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems 🌍.

Research Focus

Yu Liu’s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine

Bekri Melka Abdo | Drug Discovery and Development | Top Pharmaceutical Scientist Award

Posted on 26/03/202526/03/2025 by sciencefather

Bekri Melka Abdo | Drug Discovery and Development | Top Pharmaceutical Scientist Award

Mr. Bekri Melka Abdo, Ethiopian Institute of Agricultural Research, Ethiopia

Bekri Melka Abdo is a dedicated organic chemist specializing in natural product chemistry 🌿. With expertise in plant sample collection, extraction, compound isolation, and structure elucidation, he focuses on bioactive compounds from Ethiopia’s medicinal and aromatic plants. His research contributes to developing natural product-based treatments for leishmaniasis 🦠. He has two published journal articles, an h-index of 7, a Google patent, and an ISBN-registered book 📖. Actively engaged in research and consultancy, Bekri is committed to innovative drug discovery and advancing natural product chemistry for global health.

Publication Profile

orcid

Education

Bekri Melka Abdo is a dedicated professional in organic chemistry 🧪, specializing in natural product chemistry 🌿. His expertise encompasses plant sample collection and preparation, extraction, compound isolation, and structure elucidation. He is skilled in qualitative and quantitative analysis, as well as biological activity determination of natural products extracted from various aromatic and medicinally significant 🌱 exotic and endemic plant species of Ethiopia. With a strong foundation in the field, he contributes to the discovery and characterization of bioactive compounds, supporting advancements in medicine, pharmaceuticals, and biotechnology 🔬. His research plays a vital role in exploring Ethiopia’s rich botanical resources.

Experience

Bekri Melka Abdo is a passionate researcher in natural product chemistry 🌿, with a strong track record of research and innovation 🔬. He has successfully completed two research projects and maintains an h-index of 7 📊. His contributions extend to industry consultancy and collaborative projects, showcasing his impact in the field. He has authored a book with an ISBN 📖 and has a Google patent pending. His work is recognized in SCI and Scopus-indexed journals 🏅, with two publications. Actively engaged in editorial roles and professional memberships, he continues to drive scientific advancements in bioactive compound discovery.

Award

Bekri Melka Abdo, with his early career achievements and promising research in natural product chemistry 🌿, is an ideal candidate for the Young Scientist Award 🏆. His dedication to bioactive compound discovery, coupled with his impactful contributions to scientific research and innovation 🔬, highlights his potential for future breakthroughs. With a strong foundation in natural product extraction, analysis, and biological activity determination, he is paving the way for new discoveries in medicine and biotechnology 💊. This award category recognizes emerging researchers like Mr. Abdo, whose work demonstrates both excellence and the promise of transformative scientific advancements.

Research Focus

Mr. Bekri Melka Abdo specializes in phytochemistry and antiparasitic drug discovery, focusing on the bioassay-guided isolation of natural compounds for therapeutic applications. His research on dehydrocostus lactone from Echinops kebericho highlights its potential as a leishmanicidal drug 🦟⚕️. His work integrates natural product chemistry, pharmacognosy, and infectious disease research, contributing to novel drug development against leishmaniasis. By combining traditional medicinal plants with modern bioassays, he advances the search for effective, plant-derived antiparasitic treatments 🌱🔬. His research holds promise for addressing neglected tropical diseases through sustainable and nature-inspired therapies.

Publication Top Notes

Bioassay-guided isolation of dehydrocostus lactone from Echinops kebericho as a leishmanicidal drug

Edwin Posadas | Precision Medicine | Best Researcher Award

Posted on 12/03/202512/03/2025 by sciencefather

Edwin Posadas | Precision Medicine | Best Researcher Award

Dr. Edwin Posadas, Cedars-Sinai Cancer, United States

Dr. Edwin M. Posadas is a distinguished oncologist and urologist specializing in prostate cancer research and treatment. He is a Professor at Cedars-Sinai Medical Center and UCLA, co-Director of the Cancer Therapeutics Program, and Medical Director of the Urologic Oncology Program. A Johns Hopkins graduate, he trained at the NIH and University of Michigan. Dr. Posadas has earned numerous accolades, including Castle Connolly Top Doctor and Sigma Xi Honors. An active researcher, mentor, and leader in oncology, he contributes to multiple scientific committees and journals, shaping the future of cancer care. 📚🔬✨

Publication Profile

orcid

Education

Dr. Edwin Posadas 🎓 began his academic journey at Johns Hopkins University, earning dual B.E.S. degrees in Biomedical and Chemical Engineering (1993) with summa cum laude honors. His studies focused on biological transport systems and physiological fluid mechanics. He then pursued his M.D. at Johns Hopkins School of Medicine (1998) 🩺, followed by an internship and residency at the University of Michigan Medical Center (2001) 🏥. Further specializing, he completed a fellowship in Medical Oncology and Hematology (2005) 🧬 at the National Cancer Institute & National Heart, Lung, and Blood Institute, solidifying his expertise in cancer research and treatment. 🔬💙

Professional Associations

Dr. Edwin Posadas 🩺 is an esteemed member of numerous professional associations and scholarly societies, reflecting his dedication to oncology, urology, and medical ethics. He joined the American Medical Association (1993) 🏥, Association of Philippine Physicians of America (1998) 🇵🇭, and American College of Physicians (1998) 🩻, later becoming a Fellow (2010) 🎖️. His contributions extend to the American Society of Clinical Oncology (2001) 🧬, American Association for Cancer Research (2001) 🔬, and European Society of Medical Oncology (2012) 🌍. He also actively participates in cancer research initiatives, including the Cancer Moonshot Program (2016) 🚀 and the Medical Oncology Association of Southern California (2022) 🌿.

Achievements

Dr. Edwin Posadas 🩺 has built a distinguished career in internal medicine and medical oncology, dedicated to advancing patient care and cancer research. In 2001, he became certified in Internal Medicine 🏥, laying the foundation for his expertise in diagnosing and managing complex diseases. His passion for oncology led him to further specialize, earning his Medical Oncology certification in 2019 🧬🎗️. With decades of experience, he remains committed to innovative cancer treatments, translational research, and personalized patient care, making significant contributions to the oncology community through clinical practice, research, and professional collaborations. 🔬💙

Research Focus

Dr. Edwin M. Posadas is a distinguished researcher specializing in prostate cancer 🔬, metastasis 🧬, and nanotechnology-based diagnostics 🏥. His work focuses on understanding the molecular determinants of metastasis in prostate cancer, particularly liver and visceral metastases. He has contributed to the development of nanotechnology solutions for early cancer detection 🩸 and circulating tumor cell profiling. His research also explores the role of FYN kinase in cancer growth and motility. With multiple grants from the National Cancer Institute and Congressionally Directed Medical Research Programs, his pioneering work is advancing precision oncology and metastasis prevention in prostate cancer patients. 🎗️

Publication Top Notes

Determinants of Liver Metastasis

A Nanotechnology Solution for Early Detection of Micrometastatic Prostate Cancer After Radical Prostatectomy

A blood test to identify prostate cancer patients at risk for visceral metastasis

Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling

FYN Is a Key Regulator of Metastasis in Prostate Cancer

Targeting FYN in Prostate Cancer: A Key Regulator of Growth and Motility

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Posted on 11/03/202511/03/2025 by sciencefather

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy 🏥. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications 📑. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine 🔬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati 🎓. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch 🏥🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai 🏆, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting 🖨️🔬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey 🎖️. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University 🏅 (2000–2009) and recognized for excellence with department and presidential awards 🏆. His achievements include a scholarship from the Korean Broadcasting System 📺 and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship 🎓 (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) 🥇.

Experience

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring 📚🎤. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) 🏥. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting 🖨️ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation students—including high school, college, Ph.D., and MD candidates—on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers 🔬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology 🧪, biosensors 🧫, and biomedical engineering 🏥. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiO₂ nanotube arrays for applications in solar cells ☀️ and photocatalysis. He also explores drug discovery 💊 by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science 🏗️, biophysics ⚛️, and microfluidics 🔬 to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO₂ Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Posted on 28/02/202528/02/2025 by sciencefather

Johan Alexander Villada Ramos | Drug Discovery and Development | Best Researcher Award

Prof. Johan Alexander Villada Ramos, Universidad del Quindío, Colombia

Johan Alexander Villada Ramos is a Ph.D. candidate in Sciences at Universidad del Quindío, specializing in natural alternatives to synthetic pesticides 🌱🦠. He holds a Master’s in Biomedical Sciences, earning a meritorious distinction 🏅, and a Biology degree. His research spans bioactive plant compounds, cancer prevention, and lipid metabolism. As a university lecturer 📚, he teaches molecular biology and biochemistry. With multiple research projects, publications, and awards, including the Carlos Corredor Pereira National Award in Biomedical Sciences (2024) 🏆, Johan is a dedicated scientist pushing the boundaries of biotechnology and microbiology.

Publication Profile

Orcid

Education

Prof. Johan Alexander Villada Ramos 🎓 is a doctoral student in Sciences at the Universidad del Quindío, focusing on the bioactivity of free and microencapsulated Tagetes erecta L. 🌿 as an alternative to synthetic pesticides against the avocado weevil Heilipus lauri 🥑. He earned a Master’s in Biomedical Sciences (2018–2022) with meritorious distinction 🏅, researching the effects of Passiflora edulis extract on lipid metabolism enzymes in human colorectal adenocarcinoma cells. His Biology degree (2013–2018) involved evaluating the antibacterial activity of Tagetes patula L. against Ralstonia solanacearum. Additionally, he trained in microbiology and biotechnology lab preparation at SENA (2017–2018) 🔬.

Professional Achievements

Prof. Johan Alexander Villada Ramos 🎓 has made significant contributions to biomedical and biological research. He earned a meritorious distinction 🏅 for his master’s research on Passiflora edulis 🍊 and its effects on lipid metabolism in colorectal cancer cells. Holding a Biology degree 🔬, his studies focused on the antimicrobial activity of plant extracts against pathogens. He has been actively involved in high-impact research projects 📚 at prestigious institutions, including Pontificia Universidad Javeriana and Universidad del Quindío. His work continues to advance natural alternatives 🌱 in disease management, reinforcing his dedication to scientific discovery and innovation.

Leadership in Academia

Prof. Johan Alexander Villada Ramos 🎓 is a dedicated academic leader, serving as a lecturer 📖 in molecular biology, biochemistry, and microbiology 🔬 at Universidad del Quindío. Passionate about education, he actively contributes to curriculum development 🏫, ensuring that students receive up-to-date and high-quality training. Additionally, he plays a key role in laboratory training 🧪, equipping future scientists with essential research skills. His commitment to fostering scientific knowledge and practical expertise strengthens the university’s academic foundation, inspiring students to excel in the fields of biotechnology, microbiology, and biomedical sciences. 🚀

Research Focus

Prof. Johan Alexander Villada Ramos specializes in natural product chemistry, biochemistry, and phytopharmacology, with a strong focus on the antioxidant, antibacterial, and anticancer properties of plant extracts. His research explores bioactive compounds from medicinal plants, such as Coffea arabica ☕, Passiflora edulis 🍃, and Tagetes patula 🌼, investigating their effects on oxidative stress, protein oxidation, and bacterial inhibition 🦠. His studies contribute to pharmaceutical development, food science, and biomedicine, aiming to harness plant-derived compounds for disease prevention and therapeutic applications. 🏥

Publication Top Notes

Potencial antioxidante del extracto de hoja de Coffea arabica sobre la lipoperoxidación y oxidación proteica en un modelo de músculo bovino

Identification of potential bioactive compounds of Passiflora edulis leaf extract against colon adenocarcinoma cells

Evaluation of antibacterial activity of extract and essential oil of Tagetes patula L. in vitro against Ralstonia solanacearum biovar 2

Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Posted on 25/02/202525/02/2025 by sciencefather

Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Prof Tamara Shushpanova,Tomsk National Research Medical Center of Russian Academy of Science, Russia

🧠 Tamara Vladimirovna Shushpanova – a leading researcher at the Tomsk National Research Medical Center of the Russian Academy of Sciences, specializes in neurochemistry and neuropharmacology 🧪. Her research focuses on the benzodiazepine receptor system in addiction, studying ligand binding in alcohol dependence using molecular docking with GABAA receptor sites. She has authored 100+ scientific papers, holds 5 patents, and has contributed to major conferences (EPA, WPA, ECNP) 📚. With extensive work on innovative molecules Halodif and Halonal, her contributions drive advancements in psychiatry, pharmacology, and addiction medicine. 🎓🔬

Publication Profile

orcid

Education

Prof. Tamara Shushpanova is a dedicated researcher at the Laboratory of Neurobiology, Russian Academy of Sciences 🧠. Her work spans Neurochemistry, Clinical Pharmacology, Psychiatry, and Addiction Medicine 🏥. She has contributed significantly to understanding ethanol’s effects on the human brain and targeted therapies for correction. Notable publications include Molecular-Cellular Targets of the Pathogenetic Action of Ethanol in the Human Brain in Ontogenesis, Halonal: An Original Benzoylated Phenobarbital Derivative Anticonvulsant, and A Novel Urea Derivative Anticonvulsant 📖. Through her research, she advances treatments for neurological disorders, enhancing clinical applications and therapeutic strategies 🔬.

Professional Memberships

Prof. Tamara Shushpanova is an active member of several prestigious professional organizations in neuroscience and psychiatry 🌍. She is affiliated with the European Psychiatric Association (EPA), the World Psychiatric Association (WPA), and the European College of Neuropsychopharmacology (ECNP) 🏥. These memberships connect her with leading experts, enabling collaboration on cutting-edge research in neurochemistry, clinical pharmacology, and addiction medicine 🔬. Through these associations, she contributes to global discussions on mental health, pharmacological advancements, and innovative therapeutic strategies 🧠. Her involvement ensures she remains at the forefront of scientific progress, shaping the future of psychiatry and neurobiology 📚.

Academic Research

Prof. Tamara Shushpanova actively shares her research on ResearchGate 📚, where her contributions to neurochemistry, clinical pharmacology, and psychiatry are accessible to the global scientific community 🌍. Her profile serves as a platform for collaboration, knowledge exchange, and engagement with fellow researchers 🔬. Additionally, she provides links to relevant identification and certification documents, ensuring transparency and credibility in her academic and professional endeavors 🏅. By maintaining an active digital presence, she enhances the visibility of her work, fostering innovation and scientific progress in the field of neuroscience and pharmacology 🧠

Research Focus

Tamara Shushpanova is a distinguished researcher specializing in neuropharmacology 🧠💊, medicinal chemistry ⚗️, and molecular neuroscience 🔬. Her work primarily focuses on the development of novel anticonvulsants, particularly targeting GABAA receptors for conditions like epilepsy and alcohol withdrawal syndrome. She explores drug delivery systems 🚀, enantiomeric drug behavior 🔄, and neuroimmune interactions 🧬. Her research spans molecular docking, chemometric analysis, and in vivo pharmacological studies, contributing to innovative treatments for neurological disorders. Additionally, she investigates prenatal alcohol exposure 🍷🚼 and its impact on brain development, emphasizing glioblasts and neuronal receptor formation in neuroimmune regulation.